GP KFPs / SAQs · sexual-health-and-gender-diversity
HIV testing, PrEP, and PEP — KFP-style written assessment
KFP-style staged scenarios: window periods and RNA testing in suspected seroconversion, indicator-condition testing, PrEP initiation with baseline workup and monitoring schedule, event-driven versus daily dosing, PEP within the 72-hour clock, and U=U counselling for serodiscordant couples.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
HIV: test early and often, prevent by evidence — window periods, PrEP regimens, the PEP clock and U=U
KFP 1 (10 marks)
A 29-year-old man presents with five days of fever, sore throat, macular rash and cervical lymphadenopathy. He had receptive anal intercourse without condoms 12 days ago with a new partner. A fourth-generation HIV antigen/antibody test is negative. Monospot is negative. [9] [8]
- What is the leading diagnosis and why does the negative test not exclude it? (4) [9]
- Which test should you send now and what result pattern would confirm the diagnosis? (4) [9]
- Outline his immediate management once confirmed. (2) [6]
Model answers
- Acute retroviral syndrome (primary HIV infection): fever, pharyngitis, macular rash and lymphadenopathy 2-6 weeks after a high-risk exposure; symptoms are nonspecific and misdiagnosis as glandular fever is common. The fourth-generation assay is negative because antibody has not yet seroconverted — he is inside the window period. [9] [8]
- Send HIV RNA (viral load) now — it is the most useful test in this phase because antibody is negative or indeterminate. A high RNA with a negative antigen/antibody confirms acute infection (after repeating to exclude lab error). [9]
- Link urgently to specialist care for early antiretroviral therapy — individual benefit plus immediate transmission control during the high-viral-load phase; notify and test partners; screen for other STIs. [6]
References8ShowHide
- [1]McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet, 2016.PMID 26364263
- [2]Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med, 2015.PMID 26624850
- [3]Antoni G, Tremblay C, Delaugerre C, Charreau I, Cua E, et al. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV, 2020.PMID 31784343
- [6]Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med, 2016.PMID 27424812
- [7]Tanner MR, O'Shea JG, Byrd KM, Johnston M, Dumitru GG, et al. Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV - CDC Recommendations, United States, 2025. MMWR Recomm Rep, 2025.PMID 40331832
- [8]Adhikari EH, Macias D, Gaffney D, White S, Rogers VL, et al. Diagnostic accuracy of fourth-generation ARCHITECT HIV Ag/Ab Combo assay and utility of signal-to-cutoff ratio to predict false-positive HIV tests in pregnancy. Am J Obstet Gynecol, 2018.PMID 29913173
- [9]Chu C, Selwyn PA Diagnosis and initial management of acute HIV infection. Am Fam Physician, 2010.PMID 20507048
- [11]Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, et al. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis, 2015.PMID 25908682